Brief: Quantum genomics receives authorisation to begin Phase IIA multicentric European trial
April 26 (Reuters) - Quantum Genomics SA ALQGC.PA :
* Regulatory authorisations received in France to begin Phase IIA multicentric European
trial for heart failure
Source text for Eikon: urn:newsml:reuters.com:*:nACT43924
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study